Ritonavir API Manufacturers & Suppliers

Ritonavir (CAS 155213-67-5) is an HIV‑1 protease inhibitor indicated for use in combination antiretroviral therapy and as a pharmacokinetic booster for other protease inhibitors. It is also included in specific fixed‑dose combinations for the treatment of chronic hepatitis C virus infection and is paired with nirmatrelvir for the treatment of mild to moderate COVID‑19 in adults at high risk for progression to severe disease.

Ritonavir inhibits HIV‑1 protease, blocking cleavage of gag and gag‑pol polyprotein precursors required for maturation of infectious viral particles. This results in the production of immature, nonfunctional virions. Ritonavir’s potent inhibition of CYP3A4 is central to its boosting effect, increasing systemic exposure of co‑administered CYP3A substrates. It also interacts with transporters such as P‑glycoprotein and MRP, which can modify efflux of some protease inhibitors.

After oral administration, ritonavir is absorbed variably, undergoes extensive hepatic metabolism, and is a substrate and inhibitor of multiple drug transporters. It exhibits nonlinear pharmacokinetics due to auto‑inhibition of metabolism. Elimination occurs primarily via hepatic pathways. CYP3A4 and CYP2D6 play key roles in metabolic clearance.

Safety considerations include gastrointestinal intolerance, hepatotoxicity, dyslipidemia, and effects on glucose homeostasis. Ritonavir has extensive drug–drug interaction potential due to inhibition or induction of multiple cytochrome P450 isoenzymes and transporters, requiring careful regimen review. Its CYP3A4 inhibition can elevate concentrations of co‑administered drugs, while enzyme induction effects may reduce exposure to others. Use in HCV/HIV‑1 co‑infected patients requires fully suppressive antiretroviral therapy to limit selection of HIV protease inhibitor resistance.

Ritonavir is incorporated in approved products such as Viekira Pak, Holkira Pak, Technivie, and the nirmatrelvir plus ritonavir combination for COVID‑19.

For API procurement, sourcing should focus on manufacturers with demonstrated control of polymorph forms, impurity profiles related to complex synthesis, and capabilities for managing potent CYP3A4‑interacting compounds. Consistency in particle characteristics and stability is important for formulation and bioavailability.